Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +35

Insider Selling: Intuitive Surgical (NASDAQ:ISRG) Director Sells 400 ...

📉 Director Amy Ladd sold 72 shares for $28,303 under a pre-arranged Rule 10b5-1 trading plan on August 11th.

💰 The company reported Q2 revenue of $2.89 billion, beating estimates by $60 million and growing 18.4% year-over-year.

📈 Intuitive Surgical posted earnings per share of $2.80, significantly topping the consensus estimate of $2.48.

🏦 Institutional ownership remains high at 83.64%, with Brighton Jones LLC increasing holdings by 24.9% in Q4.

📉 Analyst Stifel Nicolaus lowered its price target from $670 to $550 while maintaining a 'buy' rating.

📉 BTIG Research reduced its price objective from $512 to $469, citing a 'buy' recommendation.

📊 The stock trades at a P/E ratio of 45.96 with a market capitalization of $141.75 billion.

🔭 Analysts forecast full-year earnings per share of $8.87 for the current fiscal year.

🏥 Intuitive Surgical's core business focuses on da Vinci robotic-assisted surgical systems and related instruments.

📈 Royal Bank Of Canada reduced its price target to $600 but maintained an 'outperform' rating.

Bullish Signals
  • Revenue of $2.89 billion exceeded analyst expectations of $2.83 billion, demonstrating strong market demand.
  • Earnings per share of $2.80 beat the consensus estimate of $2.48 by $0.32, indicating operational efficiency.
  • Year-over-year revenue growth of 18.4% highlights sustained business expansion in the medical robotics sector.
  • Net margin of 28.45% and return on equity of 16.91% reflect robust profitability and capital allocation.
  • Multiple institutional investors, including Brighton Jones LLC and Main Street Financial Solutions LLC, increased their stakes significantly in recent quarters.
Risk Factors
  • Director Amy Ladd sold a substantial portion of her holdings (28.69% decrease), which can sometimes signal reduced confidence or liquidity needs.
  • Analyst Stifel Nicolaus lowered its price target from $670 to $550, suggesting potential valuation concerns despite the buy rating.
  • BTIG Research reduced its price objective from $512 to $469, indicating a more conservative near-term outlook.
  • Royal Bank Of Canada cut its price target from $650 to $600, reflecting some caution among major financial institutions.
Full Analysis
Intuitive Surgical Director Amy Ladd sold 72 shares of the company's stock on August 11th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $393.10 per share, totaling approximately $28,303, leaving her with 179 shares valued at roughly $70,365. This sale represents a 28.69% decrease in her personal ownership stake. The medical technology company recently reported strong quarterly financial results released on July 16th. Intuitive Surgical achieved revenue of $2.89 billion, surpassing analyst expectations of $2.83 billion, and posted earnings per share of $2.80 against a consensus estimate of $2.48. Revenue grew by 18.4% year-over-year, while the company maintained a net margin of 28.45% and a return on equity of 16.91%. Institutional investor activity shows mixed signals alongside recent analyst adjustments. Several hedge funds, including Brighton Jones LLC and Main Street Financial Solutions LLC, significantly increased their stakes in the second quarter. However, major analysts like Stifel Nicolaus and BTIG Research lowered their price targets to $550 and $469 respectively, though the consensus rating remains a 'Moderate Buy' with a target price of $509.02.